-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The clinical features of atrial fibrillation (AF) after transient ischemic attack (TIA) have not been well summarized.
medsci.
The platelet targeted inhibition (POINT) trial in patients with new-onset TIA and mild ischemic stroke included adult patients with mild ischemic stroke or high-risk TIA.
The main outcome of the study was a new diagnosis of AF identified from adverse events and treatment interruption/cessation reports.
In addition to 49 patients with baseline AF, 2746 were stroke patients and 2086 were TIA patients.
Thus, in patients with cerebral ischemia, the difference between TIA and mild stroke does not stratify the risk of subsequent diagnosis of AF, which means that patients with TIA should receive similar heart rhythm monitoring as patients with ischemic stroke.
In patients with cerebral ischemia, the difference between TIA and mild stroke does not stratify the risk of subsequent diagnosis of AF, which means that patients with TIA should receive similar heart rhythm monitoring as patients with ischemic stroke.
Original source:
Hooman Kamel.